Skip to main content
. 2014 Sep 30;22(12):2142–2154. doi: 10.1038/mt.2014.157

Figure 2.

Figure 2

T cell responses of mixed-modality AMA1 immunization regimens. T cell responses were assessed in each group by ex vivo IFN-γ ELISPOT using fresh peripheral blood mononuclear cell (PBMC). All volunteers received the same prime with ChAd63 AMA1 on d0. Median responses are shown over time for the 3D7 AMA1 allele in (a) Groups 1, 2, and 3 which all received a booster immunization on day 56, and (b) Groups 1, 4, and 5 which all received a booster immunization on d112, (note Group 1 received a booster immunization at both of these time-points). (c) Median and individual IFN-γ ELISPOT responses are shown for key time-points: all volunteers combined before boosting at days 14 and 56 (n = 31) and day 112 (n = 13); 1 week after the booster immunizations (d63 and d119); and the final time-point of follow-up 24 weeks after the last immunization (d224 or d280). ***P < 0.0001, Wilcoxon matched-pairs signed rank test. (d) Frozen PBMC from 4 weeks post-booster immunization = d84 (AM, AP+, AP−) and d140 (AMP+, A_P+, and A_M), were restimulated with a pool of 3D7 AMA1-specific peptides and assayed by intracellular cytokine staining for all volunteers (except for one in Group 5 (A_M) for which cells were not available). Individual and group median responses are shown for the % CD4+ (top) and CD8+ (bottom) T cells positive for CD107a, IFN-γ, IL-2, or TNF-α. Any values <0.002% are not shown.